SclerFIX-IP
Phase 2Biologic
SclerFIX-IP is one of 23 biologic programs targeting Osteoarthritis. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Enbrel
IImmunex
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Paracetamol
GSKPreclinical
SclerFIX-IP
TTBF Genie Tissulaire
Phase 2
Naproxen Sodium
BayerPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SclerFIX-IP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- TTBF Genie Tissulaire